title: Retinal pigment epithelial tear after intravitreal bevacizumab injection.
abstract: OBJECTIVE
  To report two cases of a retinal pigment epithelial (RPE) tear after intravitreal bevacizumab injection for exudative age-related macular degeneration (AMD).
  
  
  METHODS
  Observational case series.
  
  
  METHODS
  Two patients presented with occult choroidal neovascularization secondary to AMD. Both patients received intravitreal bevacizumab injections.
  
  
  RESULTS
  The first patient developed a RPE tear shortly after a third intravitreal bevacizumab injection. The second patient developed a RPE tear 10 days after a second intravitreal bevacizumab injection.
  
  
  CONCLUSIONS
  Although RPE tears may occur spontaneously as part of the natural history of exudative AMD, patients may develop visually devastating RPE tears after repeat intravitreal bevacizumab injection. Further studies are needed to determine the incidence of RPE tears after intravitreal bevacizumab injections.
authors.affiliation: Retina Service of Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
authors.forename: Chirag P
authors.initials: CP
authors.lastname: Shah
authors.forename: Jason
authors.initials: J
authors.lastname: Hsu
authors.forename: Sunir J
authors.initials: SJ
authors.lastname: Garg
authors.forename: David H
authors.initials: DH
authors.lastname: Fischer
authors.forename: Richard
authors.initials: R
authors.lastname: Kaiser
mesh_terms: D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology; D005122:Exudates and Transudates; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy; D010857:Pigment Epithelium of Eye / Q000187:drug effects* / Q000473:pathology; D012167:Retinal Perforations / Q000139:chemically induced* / Q000175:diagnosis; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab